BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 06, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CDP323: Phase II discontinued

The partners discontinued a Phase II trial after preliminary data showed oral CDP323 failed to produce a clinically relevant benefit vs. placebo after 24 weeks in an undisclosed number of patients. The double-blind, international study...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >